Dr. Binfeng Lu, of the Hackensack Meridian CDI (IMAGE)
Caption
A new study from Dr. Binfeng Lu and colleagues at the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a previously unrecognized mechanism by which mutations in the p53 gene can limit the effectiveness of immunotherapy—while also revealing a potential strategy to overcome this resistance.
Credit
Hackensack Meridian Health
Usage Restrictions
Usage with permission
License
Original content